Second-generation antipsychotic medications and metabolic disturbance in children and adolescents

Table 5 Regression of SGA treatment duration and metabolic syndrome indices

Indices	R²	Slope coefficient	CI	P
BMI	0.17	0.51	0.25 to 0.77	0.0003*
WC	0.18	0.29	0.14 to 0.44	0.0002*
Cholesterol	0.29	0.41	0.26 to 0.57	< 0.0001*
LDL	0.28	0.53	0.33 to 0.74	< 0.0001*
HDL	0.48	− 0.44	− 0.54 to − 0.33	< 0.0001*
TG	0.13	0.29	0.12 to 0.45	0.002*
FBS	0.04	− 0.36	− 0.81 to 0.08	0.11
SBP	0.001	− 0.04	− 0.33 to 0.24	0.77
DBP	0.001	0.05	− 0.25 to 0.34	0.75
MtS score	0.18	0.04	0.02 to 0.07	0.006*

*Significance P < 0.05
CTL control, SGA second generation treated patients, R² regression, CL confidence interval; P value, BMI body mass index, WC waist circumference, LDL low density lipoprotein, HDL high density lipoprotein, TG triglycerides, FBS fasting blood sugar, MtS score metabolic syndrome score